This category covers biotechnology and pharmaceutical companies developing therapeutics that directly target ATP13A2/PARK9 for Parkinson's disease. ATP13A2 encodes a lysosomal P5-type ATPase critical for lysosomal function, metal ion homeostasis, and autophagy regulation. Loss-of-function mutations cause Kufor-Rakeb syndrome (KRS), and common variants modify sporadic PD risk.
Companies in this space are developing multiple therapeutic modalities including gene therapy, small molecule modulators, and autophagy enhancers targeting the ATP13A2 pathway.
- Focus: AAV-ATP13A2 gene replacement therapy
- Lead Candidate: NR-001 (AAV-ATP13A2)
- Indication: Parkinson's disease, Kufor-Rakeb syndrome
- Stage: Preclinical
- Mechanism: AAV-mediated delivery of functional ATP13A2 gene to restore lysosomal P5-ATPase function
- Page: NeuRon Therapeutics
Note: Prevail Therapeutics has also explored ATP13A2 gene therapy programs, see Prevail Therapeutics
TFEB (Transcription Factor EB) is the master regulator of lysosomal biogenesis. ATP13A2 dysfunction impairs TFEB signaling, making TFEB activation a complementary strategy.
- Focus: TFEB pathway activators
- Lead Candidate: ATL-02
- Indication: Parkinson's disease (ATP13A2-related)
- Stage: Preclinical
- Mechanism: Small molecule TFEB activators that enhance lysosomal biogenesis, compensating for ATP13A2 deficiency
- Page: Appvian Therapeutics
- Focus: Next-generation TFEB activators
- Lead Candidate: ATL-1001
- Indication: Parkinson's disease
- Stage: Phase I planned
- Mechanism: Oral small molecule TFEB activators with improved brain penetration
- Page: AtlasX Bio
- Focus: Autophagy enhancement for lysosomal disorders
- Lead Candidate: ZX-42
- Indication: Parkinson's disease, lysosomal storage disorders
- Stage: Preclinical
- Mechanism: mTOR-independent autophagy inducers that enhance alpha-synuclein clearance
- Page: Z-index Pharma
- Focus: Cathepsin activators and lysosomal function enhancers
- Lead Candidate: LYS-01
- Indication: Parkinson's disease
- Stage: Discovery
- Mechanism: Small molecule cathepsin D activators to enhance lysosomal proteolytic capacity
- Page: Lysosomal Therapies
- Focus: Natural product autophagy induction
- Compound: Genistein (soy isoflavone)
- Indication: Parkinson's disease (research)
- Stage: Research/preclinical
- Mechanism: Tyrosine kinase inhibition and autophagy enhancement
- Note: No dedicated company page; available as supplement
| Company |
Drug |
Mechanism |
Phase |
Indication |
| NeuRon Therapeutics |
NR-001 |
Gene therapy (ATP13A2) |
Preclinical |
PD, KRS |
| Appvian Therapeutics |
ATL-02 |
TFEB activator |
Preclinical |
PD (ATP13A2) |
| AtlasX Bio |
ATL-1001 |
TFEB activator |
Phase I planned |
PD |
| Z-index Pharma |
ZX-42 |
Autophagy inducer |
Preclinical |
PD |
| Lysosomal Therapies |
LYS-01 |
Cathepsin activator |
Discovery |
PD |
Gene therapy approaches aim to deliver functional ATP13A2 directly to neurons:
- AAV9-ATP13A2: Most advanced delivery vector, crosses blood-brain barrier
- AAV-PHP.B: Enhanced CNS transduction
- Target: Substantia nigra dopaminergic neurons
TFEB activators compensate for ATP13A2 deficiency by enhancing lysosomal biogenesis:
- mTOR-independent activation: More selective than rapamycin
- Enhanced clearance: Increases autophagic flux
- Synergy: Works alongside ATP13A2 restoration
Broad autophagy inducers address the downstream consequences of ATP13A2 loss:
- mTOR-independent pathways: Targets trehalose, genistein
- Alpha-synuclein clearance: Reduces toxic protein burden
- Mitophagy enhancement: Clears damaged mitochondria
ATP13A2 (PARK9) is a lysosomal P5-ATPase that:
- Transports calcium, manganese, and zinc across lysosomal membrane
- Regulates lysosomal acidification
- Controls autophagosome-lysosome fusion
- Mutations cause Kufor-Rakeb syndrome (KRS) - early-onset parkinsonism
ATP13A2 deficiency causes:
- Impaired lysosomal calcium buffering
- Metal ion homeostasis disruption
- Reduced autophagic flux
- Enhanced alpha-synuclein accumulation
Enhancing ATP13A2 function addresses:
- Genetic forms: KRS patients with loss-of-function mutations
- Sporadic PD: ATP13A2 expression reduced in sporadic PD brains
- Risk variants: Common polymorphisms modify PD risk
- Synergy: Combines with GBA, LRRK2-targeted approaches